|Bid||28.29 x 300|
|Ask||47.31 x 200|
|Day's Range||31.43 - 31.64|
|52 Week Range||26.26 - 31.91|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.70%|
The FDA's approval of Regeneron Pharmaceuticals' Kevzara was based on the pivotal Phase 3 MOBILITY and TARGET clinical trials.
Three reasons to dive into blue-chip ETFs right now.
ETFs can be a good choice for tax-sensitive investors, but remember they aren't tax-exempt.